• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Quantum Biopharma Ltd.

    10/28/25 8:17:06 PM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QNTM alert in real time by email
    6-K 1 form6k.htm FORM 6-K Quantum BioPharma Ltd.: Form 6-K - Filed by newsfilecorp.com

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 6-K

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    OF THE SECURITIES EXCHANGE ACT OF 1934

    For the month of October 2025

    Commission File Number: 001-39152

    QUANTUM BIOPHARMA LTD.

    (Registrant)

    1 Adelaide Street East, Suite 801

    Toronto, Ontario M5C 2V9

    (Address of Principal Executive Offices)

    Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F  ☒            Form 40-F  ☐

    Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

    Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐


    DOCUMENTS INCORPORATED BY REFERENCE

    Exhibits 99.3 through 99.11 of this Form 6-K are hereby incorporated by reference into the Registrant’s Registration Statement on Form F-3 (File No. 333-276264) and shall be deemed to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      QUANTUM BIOPHARMA LTD.
      (Registrant)
         
    Date October 28, 2025 By /s/ Donal Carroll
        Donal Carroll
        Chief Financial Officer


    EXHIBIT INDEX

    Exhibit   Description of Exhibit
       
    99.1   Material Change Report dated February 6, 2024
         
    99.2   Material Change Report dated February 26, 2024
         
    99.3   Material Change Report dated July 3, 2024
         
    99.4   Material Change Report dated August 23, 2024
         
    99.5   Material Change Report dated August 29, 2024
         
    99.6   Material Change Report dated September 13, 2024
         
    99.7   Material Change Report dated September 19, 2024
         
    99.8   Material Change Report dated October 3, 2024
         
    99.9   Material Change Report dated March 17, 2025
         
    99.10   Material Change Report dated June 27, 2025
         
    99.11   Material Change Report dated September 30, 2025


    Get the next $QNTM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QNTM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QNTM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quantum BioPharma Ltd. Provides Corporate Update

    TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K9A) ("Quantum" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that pursuant to the entry into its previously announced at the market offering agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC ("Wainwright") on February 16, 2024, announces today, the Company at its discretion may offer and sell, from time to time, through Wainwright as sales agent, Class B Subordinate Voting Shares in the capital of the Company ("Class B Shares") having an aggregate offering price of up to US$21,2

    10/31/25 7:51:27 PM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication

    TORONTO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announced its licensee, Unbuzzd Wellness Inc. ("Unbuzzd"), the company behind unbuzzdTM — the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms — as part of its Reg D 506 (c) offering and up to

    10/23/25 8:15:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

    TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the expiration at 5pm EST of 53,147 warrants (originally 3,454,543 warrants issued pre-reverse stock split (65 to 1)). All warrants were issued to hedge funds and investment funds as part of a previous financing completed on October 20, 2020. This represen

    10/20/25 8:30:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QNTM
    SEC Filings

    View All

    SEC Form 424B5 filed by Quantum Biopharma Ltd.

    424B5 - Quantum Biopharma Ltd. (0001771885) (Filer)

    10/31/25 5:29:34 PM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Quantum Biopharma Ltd.

    6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

    10/28/25 8:17:06 PM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Quantum Biopharma Ltd.

    6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

    10/28/25 6:55:06 PM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QNTM
    Financials

    Live finance-specific insights

    View All

    Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

    TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the expiration at 5pm EST of 53,147 warrants (originally 3,454,543 warrants issued pre-reverse stock split (65 to 1)). All warrants were issued to hedge funds and investment funds as part of a previous financing completed on October 20, 2020. This represen

    10/20/25 8:30:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case

    TORONTO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced today that its Board of Directors has established October 27, 2025 as the record date for the distribution of contingent value rights ("CVRs") to holders of its Class B Subordinate Voting Shares on a one-for-one basis, advancing the Company's previously disclosed plan in the Company's press release dated June 13, 2025, to deliver a litigation-linked CVR to shareholders of record as of the record date. Each CVR will entitle the holder

    10/3/25 7:00:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum BioPharma Makes Strategic Investment in GameStop Corp.

    TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to innovative therapies for neurodegenerative disorders, today announced the purchase of 2,000 shares of GameStop Corp. (NYSE:GME) to hold on the Company's balance sheet as a strategic investment. This move aligns with Quantum BioPharma's ongoing commitment to combating market corruption and enhancing shareholder value through prudent financial strategies and advocacy against manipulative trading practices. The Company has been at the forefront of fighting market corruption, as evidenced by

    7/22/25 7:00:00 AM ET
    $GME
    $QNTM
    Electronics Distribution
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QNTM
    Leadership Updates

    Live Leadership Updates

    View All

    Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders

    TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, is pleased to announce today the results of its annual general and special meeting of shareholders, held on Friday, September 26, 2025 in person at 801-1 Adelaide Street East, Toronto, ON M5C 2V9 ("AGSM"). There were shareholders represented in person or by proxy at t

    9/29/25 7:40:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor

    TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce the appointment of Kevin Malone as an advisor to the Board of Directors. Mr. Malone brings a vast wealth of successful stock trading experience, especially in manipulated companies, from his years of wealth management. About Mr. Kevin Malone Mr. Malone is a 2nd generation financial advisor with over 40 years of family experience in wealth management. This combined with his deep entrepreneurial background he launched Malone Wealth in 2021. Mr. Malone focuses deeply on pattern recognition skills and data research to diffe

    4/22/25 7:00:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors

    TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce the appointment of Terry Lynch to its board of directors. Mr. Lynch will be replacing Dr. Sanjiv Chopra, who has resigned from his position on the board. The Company thanks Dr. Chopra for his contribution so far. Dr. Chopra will continue to serve as an advisor to the company. Mr. Terry Lynch Mr. Lynch is widely known and respected for his role founding and operating Save Canadian Mining, a not-for-profit organization leading the fight against micro-cap stock market manipulation and naked short selling. Mr. Lynch has a long,

    3/27/25 7:00:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care